Forecast Alzheimer's disease progression to better select patients for clinical trials - Inria - Institut national de recherche en sciences et technologies du numérique Access content directly
Conference Papers Year : 2021

Forecast Alzheimer's disease progression to better select patients for clinical trials

Abstract

Objectives Subject recruitment is a burden that hampers clinical trials, especially in neurodegenerative diseases, where worsening of abilities is subtle, long-term and heterogeneous. Targeting the right patients during trial screening is a way to reduce the needed sample size or conversely to improve the proven effect size. Methods From Alzheimer’s disease (AD) observational cohorts, we selected longitudinal data that matched AD trials (inclusion and exclusion criteria, trial duration and primary endpoint). We modeled EMERGE, a phase 3 trial in pre-clinical AD, and a mild AD trial, using 4 research cohorts (ADNI, Memento, PharmaCog, AIBL). For each patient, we simulated its treated counterpart by applying an individual treatment effect. It consisted in a linear improvement of outcome for effective decliners, calibrated on our data so to match the expected trial effect size. Next, we built a multimodal AD course map that grasped long-term disease progression in a mixed-effects fashion [1] with Leaspy. We used it to forecast never-seen individuals’ outcomes from their screening biomarkers. Based on these individual screening predictions, we selected clinically relevant sub-groups [2]. Finally, we compared the effective sample size that would have been needed for the trial, with and without our selections. We evaluated dispersion of this metric using a bootstrap procedure. Results In all investigated setups and cohorts, we found a decrease in needed sample sizes with selection. For EMERGE trial, we showed that selecting patients having a predicted CDR-SoB changed between 0.5 and 1.5 points per year enabled to reduce the needed sample size by 38.2 ± 3.3 %. For the mild AD trial, we showed that selecting patients having a predicted MMSE changed between 1 and 2 points per year enabled to reduce the needed sample size by 38.9 ± 2.2 %. Conclusions We build a modelling framework for forecasting individual outcomes from their multimodal screening assessments. Using them as an extra inclusion criterion in clinical trials, we can better control trial population and thus reduce the needed sample size for a given treatment effect.
FORECAST ALZHEIMER.pdf (85.6 Ko) Télécharger le fichier
pres_ISCB_v2.pdf (1.88 Mo) Télécharger le fichier
Origin Files produced by the author(s)

Dates and versions

hal-03483237 , version 1 (07-01-2022)

Identifiers

  • HAL Id : hal-03483237 , version 1

Cite

Etienne Maheux, Juliette Ortholand, Colin Birkenbihl, Elina Thibeau-Sutre, Meemansa Sood, et al.. Forecast Alzheimer's disease progression to better select patients for clinical trials. ISCB 2021: 42nd Conference of the International Society for Clinical Biostatistics, Jul 2021, Online, France. ⟨hal-03483237⟩
116 View
66 Download

Share

Gmail Mastodon Facebook X LinkedIn More